Firefly Neuroscience, Inc. (AIFF) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Firefly Neuroscience, Inc. is an AI technology company developing the Brain Network Analytics (BNA) Platform, an FDA-510(k) cleared software solution for diagnosing and treating mental illnesses and neurological disorders. The company is currently in the pre-commercial stage, focusing on commercializing the BNA Platform in 2025 through neurological clinics and pharmaceutical collaborations. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $43,000 | $12,000 |
| Net Loss | $(12,930,000) | $(1,122,000) |
| Net Loss Attributable to Common Stockholders | $(17,340,000) | $(1,122,000) |
| Operating Loss | $(2,065,000) | $(1,091,000) |
| Cash and Cash Equivalents (End of Period) | $9,545,000 | $1,638,000 |
| Net Cash Used in Operating Activities | $(2,511,000) | $(1,319,000) |
| Net Cash Provided by Financing Activities | $10,253,000 | $945,000 |
| Total Assets | $12,363,000 | $4,601,000 |
| Total Liabilities | $7,178,000 | $4,976,000 |
| Shares Outstanding (as of May 11, 2025) | 12,861,098 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 258% to $43,000, driven by increased customers, BNA scans, and clinical study revenue.
- Significant Non-Cash Losses: The Net Loss of $12.9 million was heavily impacted by non-cash items, including a $9.37 million loss on the change in derivative fair value and a $1.35 million loss on the settlement of a convertible promissory note. Additionally, a $4.41 million deemed dividend was recorded related to a warrant inducement agreement.
- Expense Increases: General and Administrative (G&A) expenses surged 181% to $1.59 million, primarily due to audit/accounting fees, insurance, and investor relations costs. Research and Development (R&D) expenses rose 8% to $312,000.
- Liquidity Improvement: Cash balances increased from $1.81 million to $9.55 million, primarily due to $8.83 million in proceeds from warrant exercises and $1.43 million from a private placement (PIPE 2025).
- Debt Elimination: The company converted a $2.4 million convertible promissory note into 800,000 shares of common stock, eliminating the associated debt liability.
Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $104.4 million and expects to continue generating losses. Future operations depend on raising additional capital.
- Subsequent Acquisition: On April 30, 2025, the company acquired Evoke Neuroscience, Inc. for approximately $6 million ($3 million cash + stock). This transaction is not reflected in the Q1 financial statements but impacts future liquidity and operations.
- Commercialization Plan: Management plans to launch the BNA Platform commercially in 2025, targeting neurologists and pharmaceutical companies. No material additional development costs are expected for the launch.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of March 31, 2025, citing material weaknesses in IT general controls and segregation of duties. A remediation plan is underway.
- Equity Line of Credit: The company has an equity line of credit allowing for up to $10 million in share sales, though no shares were issued under this agreement as of March 31, 2025.
Investor Verification Checklist
- Cash Burn Rate: Verify the monthly cash burn rate given the "substantial doubt" going concern warning and the recent $3 million cash outlay for the Evoke acquisition.
- Capital Raise Progress: Monitor the status of the $10 million equity line of credit and any new financing efforts to ensure operational continuity beyond the current cash balance.
- Revenue Sustainability: Assess whether the $43,000 in Q1 revenue is a sustainable trend or a one-time result of specific clinical studies, given the pre-commercial status of the core product.
- Integration Risks: Evaluate the integration plan and financial impact of the Evoke Neuroscience acquisition, including potential earn-out liabilities up to $500,000.
- Internal Control Remediation: Review future filings to confirm the remediation of material weaknesses in internal controls over financial reporting.